A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeOne Medicines
BeOne Medicines
Hoffmann-La Roche
Lumos Pharma
Incyte Corporation
Eisai Inc.
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Hoffmann-La Roche
AstraZeneca
Novartis
Merck Sharp & Dohme LLC
Hoffmann-La Roche
BeOne Medicines
AstraZeneca
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
AstraZeneca
Merck Sharp & Dohme LLC
Palleos Healthcare GmbH
Astellas Pharma Inc
Bristol-Myers Squibb
AstraZeneca
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Tesaro, Inc.
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Gilead Sciences
Incyte Corporation
Bristol-Myers Squibb
Eli Lilly and Company
Merck Sharp & Dohme LLC
Incyte Corporation
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb
Daiichi Sankyo
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
BeiGene
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Mural Oncology, Inc
AbbVie
BeiGene
Incyte Corporation
American Regent, Inc.
Leap Therapeutics, Inc.